New England Biolabs Launches Monarch Mag cfRNA Extraction Kit
Ipswich, Massachusetts – August 4, 2026 New England Biolabs (NEB®) has expanded its molecular biology portfolio with the launch...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Ipswich, Massachusetts – August 4, 2026 New England Biolabs (NEB®) has expanded its molecular biology portfolio with the launch...
LEXINGTON, Mass., July 2, 2026 Partner Therapeutics (PTx) has announced the publication of pivotal results from the Phase 2...
SOUTH SAN FRANCISCO, Calif., May 2026 Mission Bio announced new data demonstrating the power of its Targeted Single-Cell DNA+RNA...
LAGUNA HILLS, CALIFORNIA, April 29, 2026 PreludeDx has announced that the U.S. Food and Drug Administration (FDA) has granted...
MONTEVIDEO, Uruguay & NEW YORK, United States, April 7, 2026 Resolve Therapeutics and the Institut Pasteur de Montevideo announced...
CHICAGO — March 11, 2026 Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence...
